NG2 as an Identity and Quality Marker of Mesenchymal Stem Cell Extracellular Vesicles

The therapeutic potential of mesenchymal stem cell (MSC) extracellular vesicles (EV) is currently under investigation in many pathological contexts. Both adult and perinatal MSC are being considered as sources of EV. Herein, we address antigen expression of cord blood and bone marrow MSC and released EV to define an identity and quality parameter of MSC EV as a medicinal product in the context of clinical applications. The research focuses on EV-shuttled neural/glial antigen 2 (NG2), which has previously been detected as a promising surface marker to distinguish perinatal versus adult MSC. Indeed, NG2 was significantly more abundant in cord blood than bone marrow MSC and MSC EV. Ultracentrifuge-isolated EV were then challenged for their pro-angiogenic properties on an xCELLigence system as quality control. NG2+ cord blood MSC EV, but not bone marrow MSC EV, promote bFGF and PDGF-AA proliferative effect on endothelial cells. Likewise, they successfully rescue angiostatin-induced endothelial cell growth arrest. In both cases, the effects are NG2-dependent. These results point at NG2 as an identity and quality parameter for cord blood MSC EV, paving the way for their clinical translation.

Download Full-text

MiRNAs and piRNAs from bone marrow mesenchymal stem cell extracellular vesicles induce cell survival and inhibit cell differentiation of cord blood hematopoietic stem cells: a new insight in transplantation

Oncotarget ◽

10.18632/oncotarget.6791 ◽

2015 ◽

Vol 7 (6) ◽

pp. 6676-6692 ◽

Cited By ~ 49

Author(s):

Luciana De Luca ◽

Stefania Trino ◽

Ilaria Laurenzana ◽

Vittorio Simeon ◽

Giovanni Calice ◽

...

Keyword(s):

Stem Cells ◽

Bone Marrow ◽

Stem Cell ◽

Cell Differentiation ◽

Mesenchymal Stem Cell ◽

Hematopoietic Stem Cells ◽

Cord Blood ◽

Cell Survival ◽

Extracellular Vesicles ◽

Hematopoietic Stem

Download Full-text

Concise Review: Therapeutic Potential of the Mesenchymal Stem Cell Derived Secretome and Extracellular Vesicles for Radiation-Induced Lung Injury: Progress and Hypotheses

Stem Cells Translational Medicine ◽

10.1002/sctm.18-0038 ◽

2019 ◽

Vol 8 (4) ◽

pp. 344-354 ◽

Cited By ~ 21

Author(s):

Siguang Xu ◽

Cong Liu ◽

Hong-Long Ji

Keyword(s):

Stem Cell ◽

Mesenchymal Stem Cell ◽

Lung Injury ◽

Extracellular Vesicles ◽

Therapeutic Potential ◽

Concise Review ◽

Radiation Induced

Download Full-text

Mesenchymal stem cell-derived extracellular vesicles may promote breast cancer cell dormancy

Journal of Tissue Engineering ◽

10.1177/2041731418810093 ◽

2018 ◽

Vol 9 ◽

pp. 204173141881009 ◽

Cited By ~ 4

Author(s):

Jake Casson ◽

Owen G Davies ◽

Carol-Anne Smith ◽

Matthew J Dalby ◽

Catherine C Berry

Keyword(s):

Breast Cancer ◽

Bone Marrow ◽

Cell Proliferation ◽

Stem Cell ◽

Mesenchymal Stem Cell ◽

Cancer Cells ◽

Cancer Cell ◽

Extracellular Vesicles ◽

Breast Cancer Cells ◽

Cell Dormancy

Disseminated breast cancer cells have the capacity to metastasise to the bone marrow and reside in a dormant state within the mesenchymal stem cell niche. Research has focussed on paracrine signalling factors, such as soluble proteins, within the microenvironment. However, it is now clear extracellular vesicles secreted by resident mesenchymal stem cells into this microenvironment also play a key role in the initiation of dormancy. Dormancy encourages reduced cell proliferation and migration, while upregulating cell adhesion, thus retaining the cancer cells within the bone marrow microenvironment. Here, MCF7 breast cancer cells were treated with mesenchymal stem cell–derived extracellular vesicles, resulting in reduced migration in two-dimensional and three-dimensional culture, with reduced cell proliferation and enhanced adhesion, collectively supporting cancer cell dormancy.

Download Full-text

1385 Dual mechanism of Type VII collagen transfer by bone marrow mesenchymal stem cell extracellular vesicles to recessive dystrophic epidermolysis bullosa fibroblasts

Journal of Investigative Dermatology ◽

10.1016/j.jid.2018.03.1402 ◽

2018 ◽

Vol 138 (5) ◽

pp. S235

Author(s):

J. McBride ◽

E. Badiavas

Keyword(s):

Bone Marrow ◽

Stem Cell ◽

Mesenchymal Stem Cell ◽

Extracellular Vesicles ◽

Epidermolysis Bullosa ◽

Dystrophic Epidermolysis Bullosa ◽

Type Vii Collagen ◽

Recessive Dystrophic Epidermolysis Bullosa ◽

Dual Mechanism

Download Full-text

Treating amyotrophic lateral sclerosis with a bone marrow derived mesenchymal stem cell extracellular vesicles - A case report

International Journal of Science and Research Archive ◽

10.30574/ijsra.2021.2.2.0058 ◽

2021 ◽

Vol 2 (2) ◽

pp. 167-171

Author(s):

Joshua James Crose

Keyword(s):

Bone Marrow ◽

Amyotrophic Lateral Sclerosis ◽

Stem Cell ◽

Case Report ◽

Mesenchymal Stem Cell ◽

Extracellular Vesicles ◽

Treatment Options ◽

Future Studies ◽

Functional Scores ◽

Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a terminal neurodegenerative disease with only a few minimally effective treatment options. This study treats a patient with Spinal ALS with Bone Marrow Derived Mesenchymal Stem Cell Extracellular Vesicles (BM-MSCEVs) to slow or stop the progress of the disease. After 2 months and 4 treatments, the patient demonstrated improvement in ALS functional scores and most physical exam findings. BM-MSCEVs demonstrate the ability to effectively treat Spinal ALS in this study and open the door for future studies.

Download Full-text